Aarti Drugs witnessed a decline of over 2% in its share price following the release of its financial results for the second quarter of FY25.
The company’s performance showed a noticeable drop in both revenue and profit compared to the same period last year, raising concerns among investors.
Key Financial Highlights
- Revenue from operations: ₹543.09 crore, down 6.3% from ₹577.54 crore in Q2 FY24.
- Total income: ₹543.47 crore, down 6.2% from ₹578.28 crore in Q2 FY24.
- Profit before tax (PBT): ₹40.99 crore, down 12.5% from ₹46.83 crore in the same quarter last year.
- Profit after tax (PAT): ₹30.39 crore, down 12.1% from ₹34.58 crore in Q2 FY24.
- Total expenses: ₹502.58 crore, down slightly by 5.4% compared to ₹531.45 crore in Q2 FY24.
Stock Performance Today
- Open: ₹471.00
- Day High: ₹479.75
- Day Low: ₹466.10
As of 11:33 am, Aarti Drugs shares were trading 2.63% lower at Rs 472.15 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
